Felix Biotechnology is a biotherapeutics company with a focus on microbial challenges in human health. Felix Biotechnology is developing precision phage therapy to manage antibiotic-resistant bacterial infection, using a phage licensed from Yale University and discovery and engineering platforms from University of Califoria Berkeley.
Felix Biotechnology’s technology has been deployed to treat multidrug resistant (MDR) bacteria and pan-drug resistant (PDR) Pseudomonas aeruginosa infections in cystic fibrosis patients using a compassionate use IND. The company also has candidates to target S. aureus, MRSA infections, Burkhholderia and Acinetobacter as well as discovery biotherapeutics targeting certain fungal infections.
Timeline
People
Paul Turner
Founder